Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25705161 | 0.98 | PIK3CD (0.42) | PIK3CDGGPS1CHRM2 | |
| SCHEMBL15383400 | 0.98 | PIK3CD (0.42) | PIK3CDGGPS1CHRM2 | |
| SCHEMBL15183475 | 0.93 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL13656355 | 0.84 | PIK3CD (0.48) | PIK3CD | |
| SCHEMBL25926648 | 0.83 | PIK3CD (0.41) | PIK3CDGGPS1 | |
| SCHEMBL21965389 | 0.83 | CHRM2 (0.37) | GGPS1CHRM2 | |
| SCHEMBL25500879 | 0.82 | PIK3CD (0.39) | PIK3CDGGPS1 | |
| SCHEMBL26455602 | 0.81 | CHRM2 (0.43) | GGPS1CHRM2 | |
| SCHEMBL26455608 | 0.81 | CHRM2 (0.43) | GGPS1CHRM2 | |
| SCHEMBL13602680 | 0.80 | CYP1A2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| US-9890198-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890198-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2016-02-25 | — | — | US | disclosed |
| US-9217015-B2 | Cyclosporin derivatives for the treatment and prevention of a viral infection | S&T GLOBAL INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130303438-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130210704-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2013-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, ICOS | PIK3CD 3271/4885GGPS1 2218/4885CHRM2 4645/4885 |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | PIK3CD 2967/4885GGPS1 3932/4885CHRM2 4463/4885 |
| US-20130210704-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | PIK3CD 3034/4885GGPS1 3958/4885CHRM2 4339/4885 |
| US-20130303438-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, ICOS | PIK3CD 3271/4885GGPS1 2218/4885CHRM2 4645/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | PIK3CD 3034/4885GGPS1 3958/4885CHRM2 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.